180 related articles for article (PubMed ID: 11727405)
21. TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats.
Tsujihata Y; Ito R; Suzuki M; Harada A; Negoro N; Yasuma T; Momose Y; Takeuchi K
J Pharmacol Exp Ther; 2011 Oct; 339(1):228-37. PubMed ID: 21752941
[TBL] [Abstract][Full Text] [Related]
22. Pharmacologic therapy for type 2 diabetes mellitus.
DeFronzo RA
Ann Intern Med; 1999 Aug; 131(4):281-303. PubMed ID: 10454950
[TBL] [Abstract][Full Text] [Related]
23. Reduction of cardiovascular morbidity and mortality in type 2 diabetes. A rational approach to hypoglycemic therapy.
Spallarossa P; Barsotti A; Cordera R; Ghigliotti G; Maggi D; Brunelli C
J Endocrinol Invest; 2004 May; 27(5):485-95. PubMed ID: 15279085
[TBL] [Abstract][Full Text] [Related]
24. Liberal Glycemic Control in Critically Ill Patients With Type 2 Diabetes: An Exploratory Study.
Kar P; Plummer MP; Bellomo R; Jenkins AJ; Januszewski AS; Chapman MJ; Jones KL; Horowitz M; Deane AM
Crit Care Med; 2016 Sep; 44(9):1695-703. PubMed ID: 27315191
[TBL] [Abstract][Full Text] [Related]
25. A model of type 2 diabetes in the guinea pig using sequential diet-induced glucose intolerance and streptozotocin treatment.
Podell BK; Ackart DF; Richardson MA; DiLisio JE; Pulford B; Basaraba RJ
Dis Model Mech; 2017 Feb; 10(2):151-162. PubMed ID: 28093504
[TBL] [Abstract][Full Text] [Related]
26. A Randomized Trial of Insulin Glargine plus Oral Hypoglycemic Agents versus Continuous Subcutaneous Insulin Infusion to Treat Newly Diagnosed Type 2 Diabetes.
Lin S; Chen M; Chen W; Lin K; Mu P; Zhu B; Xu W; Wang M; Weng J; Zeng L
J Diabetes Res; 2018; 2018():2791584. PubMed ID: 30420969
[TBL] [Abstract][Full Text] [Related]
27. Timely initiation of basal insulin.
Riddle MC
Am J Med; 2004 Feb; 116 Suppl 3A():3S-9S. PubMed ID: 15013454
[TBL] [Abstract][Full Text] [Related]
28. Status of basal-supported oral therapy in Chinese type 2 diabetic patients with inadequate glycemic control on oral anti-diabetic drugs.
Xu W; Qiu L; Luo S; Li M; Weng J; Guo X; Ji L
Diabetes Metab Res Rev; 2015 Nov; 31(8):796-802. PubMed ID: 26356031
[TBL] [Abstract][Full Text] [Related]
29. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice.
Tahara A; Kurosaki E; Yokono M; Yamajuku D; Kihara R; Hayashizaki Y; Takasu T; Imamura M; Li Q; Tomiyama H; Kobayashi Y; Noda A; Sasamata M; Shibasaki M
Eur J Pharmacol; 2013 Sep; 715(1-3):246-55. PubMed ID: 23707905
[TBL] [Abstract][Full Text] [Related]
30. Type 2 diabetes - controlling hyperglycaemia with early insulin use.
MacIsaac R; Cheung A; Jerums G
Aust Fam Physician; 2010 Aug; 39(8):565-9. PubMed ID: 20877750
[TBL] [Abstract][Full Text] [Related]
31. Insulin secretagogues: who, what, when, and how?
Dailey G
Curr Diab Rep; 2005 Oct; 5(5):329-32. PubMed ID: 16188166
[TBL] [Abstract][Full Text] [Related]
32. Cost-effective management of hyperglycemia in patients with type 2 diabetes using oral agents.
Kabadi UM
Manag Care; 2004 Jul; 13(7):48-9, 53-6, 58-9. PubMed ID: 15347160
[TBL] [Abstract][Full Text] [Related]
33. Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, parallel-group trial.
Tan M; Johns D; González Gálvez G; Antúnez O; Fabián G; Flores-Lozano F; Zúñiga Guajardo S; Garza E; Morales H; Konkoy C; Herz M;
Clin Ther; 2004 May; 26(5):680-93. PubMed ID: 15220012
[TBL] [Abstract][Full Text] [Related]
34. Mulberry (Morus alba L.) Fruit Extract Containing Anthocyanins Improves Glycemic Control and Insulin Sensitivity via Activation of AMP-Activated Protein Kinase in Diabetic C57BL/Ksj-db/db Mice.
Choi KH; Lee HA; Park MH; Han JS
J Med Food; 2016 Aug; 19(8):737-45. PubMed ID: 27441957
[TBL] [Abstract][Full Text] [Related]
35. Effect of exercise training on doses of oral agents and insulin.
Fujinuma H; Abe R; Yamazaki T; Seino H; Kikuchi H; Hoshino T; Hirano R; Yoshida S
Diabetes Care; 1999 Oct; 22(10):1754-5. PubMed ID: 10526756
[No Abstract] [Full Text] [Related]
36. Clinical significance of targeting postprandial and fasting hyperglycemia in managing type 2 diabetes mellitus.
Fonseca V
Curr Med Res Opin; 2003; 19(7):635-41. PubMed ID: 14606987
[TBL] [Abstract][Full Text] [Related]
37. Managing postprandial glucose levels in patients with diabetes.
Tenzer-Iglesias P; Brunton S
J Fam Pract; 2008 Jan; 57(1 Suppl Managing):S17-24. PubMed ID: 18662529
[No Abstract] [Full Text] [Related]
38. Potential new treatments for type 2 diabetes.
Bailey CJ
Trends Pharmacol Sci; 2000 Jul; 21(7):259-65. PubMed ID: 10871894
[TBL] [Abstract][Full Text] [Related]
39. An integrated model for the glucose-insulin system.
Silber HE; Jauslin PM; Frey N; Karlsson MO
Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):189-94. PubMed ID: 20050839
[TBL] [Abstract][Full Text] [Related]
40. Advances in oral therapy for type 2 diabetes.
Davis SN
Postgrad Med; 2000 May; 107(6 Suppl Key):16-20. PubMed ID: 19667506
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
